Form 4: DiaMedica Therapeutics Director Acquires Shares and Stock Options
SEC Form 4 Filing
Director Charles Pauling Semba reports acquisition of shares and stock options in DiaMedica Therapeutics.
Summary
- Charles Pauling Semba, a director of DiaMedica Therapeutics Inc. [DMAC], reported a transaction on June 1, 2024.
- Semba acquired 28,472 stock options with an exercise price of $2.90, expiring on May 31, 2034.
- These options vest in four nearly equal quarterly installments over one year.
- Semba also directly owns 39,318 voting common shares, which includes 7,031 shares issuable on vesting of a restricted stock unit award.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The director's acquisition of shares and options suggests confidence, but it's a routine transaction.
Positives
- The director's acquisition of stock options and shares could be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company insiders, such as directors, and their confidence in the company's stock.
Key Dates
| Date | Description |
|---|---|
| 06/01/2024 | Date of transaction: acquisition of stock options. |
| 06/03/2024 | Date of signature for the Form 4 filing. |
| 05/31/2034 | Expiration date of the acquired stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.